



Practitioner's Docket No.: 8009-7004-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of: Elizabeth Shanahan-Prendergast

Ser. No.: 09/254,623

Art Unit: 1642

Filed: July 8, 1999

Examiner: Davis, M.

For: Therapeutic Formulations Containing Venom or Venom Anti-Serum Either Alone or in Combination for the Therapeutic Prophylaxis and Therapy of Neoplasms

1#11/B
10-6-00

Assistant Commissioner For Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail addressed to Assistant Commissioner for Patents, Washington D.C. 20231, on September 19, 2000.
Janet M. Stevens
Janet M. Stevens

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action mailed March 20, 2000, please amend the above-identified application as follows:

In the Claims:

Please amend claims 1, 6, 12, 16, 38, 58 - 72 as follows:

1. (Amended) A method of treating neoplasm in a mammal in need of such treatment, comprising administering to said mammal a therapeutic agent comprising [venom and/or] mammalian, plant or insect anti-serum reactive with at least one Phospholipase A₂ type enzyme.

6. (Amended) A pharmaceutical formulation [containing venom and/or] comprising mammalian plant or insect anti-serum to PLA₂ enzyme or part thereof in combination with anti-serum to Phospholipase C enzyme or part thereof [or] and/or at least one inhibitory [compounds] compound to Phospholipase C for use as a therapeutic agent for the therapy of a neoplastic condition in a human or animal.

09/27/2000 CVD111 00000048 09254623

01 FC:202	117.00 OP
02 FC:203	198.00 OP
03 FC:228	925.00 OP